Approved Technologies

The SAFETY Act provides two levels of liability protections for approval: Designation and Certification. By obtaining either Designation or Certification, companies obtain a level of legal protection in case their technology is ever put to use during a terrorist attack. See below for a list of approved technology certifications.

Company/Technology
Human Genome Sciences, Inc. Approved: April 10, 2012 | Expires: April 30, 2017 Human Genome Sciences, Inc., provides ABthrax™. The Technology is a fully human monoclonal antibody drug against the protective antigen component of anthrax toxin. It is intended for use as part of the Strategic National Stockpile or for use in emergency situations when deemed prudent by the appropriate regulatory body. The Technology acts as a prophylactic and therapeutic product by preventing anthrax-related toxins from infiltrating and destroying human cells. As a prophylactic and a therapeutic, the Technology is administered intravenously. The Technology also includes: manufacturing, testing, labeling, packaging, and storage of the antibody product; clinical use instructions; services related to developing and testing the antibody product; and associated technical documents and manuals.
Human Genome Sciences, Inc.: ABthrax Approved: August 14, 2007 | Expires: September 30, 2012 Human Genome Sciences, Inc. provides ABthrax, a human monoclonal antibody drug against the protective antigen component of anthrax toxin, for use as part of the Strategic National Stockpile. The Technology acts as a prophylactic and therapeutic product by preventing anthrax-related toxin from infiltrating and destroying human cells.